F. Bustin

764 total citations
11 papers, 459 citations indexed

About

F. Bustin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, F. Bustin has authored 11 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in F. Bustin's work include Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer therapeutics and mechanisms (2 papers). F. Bustin is often cited by papers focused on Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer therapeutics and mechanisms (2 papers). F. Bustin collaborates with scholars based in Belgium, United States and Germany. F. Bustin's co-authors include Rafat Ansari, John D. Hainsworth, Gregory A. Otterson, Chang-Heok Soh, Gordana Vlahovic, Roy S. Herbst, Lowell L. Hart, Paula G. O’Connor, Patrick J. Flynn and Sergey Yurasov and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

F. Bustin

10 papers receiving 450 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Bustin Belgium	6	354	336	122	47	33	11	459
Edit Csada Hungary	7	280 0.8×	249 0.7×	153 1.3×	53 1.1×	24 0.7×	9	380
Joseph Burke United States	5	499 1.4×	400 1.2×	98 0.8×	62 1.3×	18 0.5×	7	572
Dario Nicolella Italy	9	158 0.4×	227 0.7×	108 0.9×	45 1.0×	37 1.1×	16	332
Kosei Tajima Japan	8	611 1.7×	529 1.6×	150 1.2×	98 2.1×	24 0.7×	15	706
M. Lomas Spain	7	364 1.0×	419 1.2×	94 0.8×	52 1.1×	22 0.7×	23	518
Tomohiro Sakamoto Japan	11	257 0.7×	237 0.7×	101 0.8×	78 1.7×	30 0.9×	47	461
Laura Emerson United States	5	285 0.8×	246 0.7×	89 0.7×	76 1.6×	29 0.9×	5	354
Eisuke Kurihara Japan	8	113 0.3×	148 0.4×	110 0.9×	48 1.0×	32 1.0×	12	271
U.P. Strauss Germany	10	319 0.9×	238 0.7×	224 1.8×	139 3.0×	65 2.0×	14	505
Alessandro Bertolini Italy	11	532 1.5×	515 1.5×	124 1.0×	65 1.4×	22 0.7×	22	760

Countries citing papers authored by F. Bustin

Since Specialization

Citations

This map shows the geographic impact of F. Bustin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Bustin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Bustin more than expected).

Fields of papers citing papers by F. Bustin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Bustin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Bustin. The network helps show where F. Bustin may publish in the future.

Co-authorship network of co-authors of F. Bustin

This figure shows the co-authorship network connecting the top 25 collaborators of F. Bustin. A scholar is included among the top collaborators of F. Bustin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Bustin. F. Bustin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Navarro, Alejandro, Egbert F. Smit, Enric Carcereny, et al.. (2023). P2.17-06 Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial. Journal of Thoracic Oncology. 18(11). S380–S381.

Joris, Sofie, Thierry Pieters, Anne Sibille, et al.. (2019). Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program. Journal of Geriatric Oncology. 11(5). 796–801. 9 indexed citations

Renson, Audrey, Alain Delobbe, & F. Bustin. (2018). [Mediastinitis following EBUS : about a complication after a minimally invasive investigation].. PubMed. 73(7-8). 387–393. 1 indexed citations

Gridelli, Cesare, Filippo de Marinis, Michael Thomas, et al.. (2014). Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study. Journal of Thoracic Oncology. 9(7). 991–997. 40 indexed citations

Doebele, Robert C., David R. Spigel, Mustapha Tehfé, et al.. (2014). Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer. Cancer. 121(6). 883–892. 59 indexed citations

Meerbeeck, Jan P. van, et al.. (2013). Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study). European Journal of Cancer Care. 23(3). 370–379. 5 indexed citations

O’Brien, Mary, Paul Lorigan, Lionel Bosquée, et al.. (2011). Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062. European Journal of Cancer. 47(15). 2322–2330. 21 indexed citations

Herbst, Roy S., Rafat Ansari, F. Bustin, et al.. (2011). Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. The Lancet. 377(9780). 1846–1854. 316 indexed citations

O’Brien, Mary, Jacek Jassem, Paul Lorigan, et al.. (2010). Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).. Journal of Clinical Oncology. 28(15_suppl). 7052–7052. 2 indexed citations

10.

Bustin, F., et al.. (2005). Diabète insipide dans le cadre d’un carcinome pulmonaire à petites cellules : un paradoxe ?. Annales d Endocrinologie. 66(4). 355–360. 5 indexed citations

11.

Bustin, F., et al.. (1997). [Energy expenditure in man].. PubMed. 52(2). 101–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact